

IN THE CLAIMS:

This listing of the claims replaces all prior versions and listings of the claims.

Please amend the claims as follows.

Claims 1 to 134. (Canceled)

135. (New) A method of treating fibromyalgia, the method consisting essentially of administering to a patient in need thereof an effective amount of at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, and an effective amount of at least one additional compound selected from gabapentin, pregabalin, pramipexole, L-DOPA, tizanidine, clonidine, tramadol, morphine, codeine, and carbamazepine, and pharmaceutically acceptable salts thereof.

136. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from gabapentin and a pharmaceutically acceptable salt thereof.

137. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from pregabalin and a pharmaceutically acceptable salt thereof.

138. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from pramipexole and a pharmaceutically acceptable salt thereof.

139. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from L-DOPA and a pharmaceutically acceptable salt thereof.

140. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from tizanidine and a pharmaceutically acceptable salt thereof.

141. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from clonidine and a pharmaceutically acceptable salt thereof.

142. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from tramadol and a pharmaceutically acceptable salt thereof.

143. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from morphine and a pharmaceutically acceptable salt thereof.

144. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from codeine and a pharmaceutically acceptable salt thereof.

145. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from carbamazepine and a pharmaceutically acceptable salt thereof.

146. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in the same dosage form.

147. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in separate dosage forms.

148. (New) The method of claim 147, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are administered simultaneously.

149. (New) The method of claim 147, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are administered separately.

150. (New) The method of claim 146, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in the same oral dosage form.

151. (New) The method of claim 147, wherein the milnacipran and at least one additional compound are in separate oral dosage forms.

152. (New) The method of claim 135, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is in tablet form.

153. (New) A method of treating chronic fatigue syndrome, the method consisting essentially of administering to a patient in need thereof an effective amount of at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, and an effective amount of at least one additional compound selected from gabapentin, pregabalin, pramipexole, L-DOPA, tizanidine, clonidine, tramadol, morphine, codeine, and carbamazepine, and pharmaceutically acceptable salts thereof.

154. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from gabapentin and a pharmaceutically acceptable salt thereof.

155. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from pregabalin and a pharmaceutically acceptable salt thereof.

156. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from pramipexole and a pharmaceutically acceptable salt thereof.

157. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is

administered with at least one additional compound selected from I-DOPA and a pharmaceutically acceptable salt thereof.

158. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from tizanidine and a pharmaceutically acceptable salt thereof.

159. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from clonidine and a pharmaceutically acceptable salt thereof.

160. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from tramadol and a pharmaceutically acceptable salt thereof.

161. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from morphine and a pharmaceutically acceptable salt thereof.

162. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from codeine and a pharmaceutically acceptable salt thereof.

163. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from carbamazepine and a pharmaceutically acceptable salt thereof.

164. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in the same dosage form.

165. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in separate dosage forms.

166. (New) The method of claim 165, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are administered simultaneously.

167. (New) The method of claim 165, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are administered separately.

168. (New) The method of claim 164, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in the same oral dosage form.

169. (New) The method of claim 165, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in separate oral dosage forms.

170. (New) The method of claim 153, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is in tablet form.

171. (New) A method of treating pain, the method consisting essentially of administering to a patient in need thereof an effective amount of at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof, and an effective amount of at least one additional compound selected from gabapentin, pregabalin, pramipexole, L-DOPA, tizanidine, clonidine, tramadol, morphine, codeine, and carbamazepine, and pharmaceutically acceptable salts thereof.

172. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from gabapentin and a pharmaceutically acceptable salt thereof.

173. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is

administered with at least one additional compound selected from pregabalin and a pharmaceutically acceptable salt thereof.

174. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from pramipexole and a pharmaceutically acceptable salt thereof.

175. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from L-DOPA and a pharmaceutically acceptable salt thereof.

176. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from tizanidine and a pharmaceutically acceptable salt thereof.

177. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from clonidine and a pharmaceutically acceptable salt thereof.

178. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from tramadol and a pharmaceutically acceptable salt thereof.

179. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from morphine and a pharmaceutically acceptable salt thereof.

180. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from codeine and a pharmaceutically acceptable salt thereof.

181. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is administered with at least one additional compound selected from carbamazepine and a pharmaceutically acceptable salt thereof.

182. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in the same dosage form.

183. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in separate dosage forms.

184. (New) The method of claim 183, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are administered simultaneously.

185. (New) The method of claim 183, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are administered separately.

186. (New) The method of claim 182, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in the same oral dosage form.

187. (New) The method of claim 183, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof and at least one additional compound are in separate oral dosage forms.

188. (New) The method of claim 171, wherein the at least one compound selected from milnacipran and a pharmaceutically acceptable salt thereof is in tablet form.